🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Tacrolimus

    Hospital Authority, Hong Kong

    Graft vs Host Disease

    phase 3 small molecule completed

    1 trial

  2. Tacrolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Transplantation

    phase 3 small molecule active

    1 trial

  3. Tacrolimus capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  4. Tacrolimus capsules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 3 small molecule completed

    1 trial

  5. Taldefgrobep, Placebo Solution for injection in pre-filled syringe, Taldefgrobep

    Lacuna Pharma Pty Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  6. Tamoxifen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Female

    phase 3 small molecule active

    1 trial

  7. Tamoxifen

    International Peace Maternity and Child Health Hospital

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  8. Tang-min Lin pill

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  9. Taping and Sham Taping

    Hospital Authority, Hong Kong

    Stroke

    phase 3 other completed

    1 trial

  10. Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)

    United Therapeutics Europe Ltd

    Critical Illness

    phase 3 other active

    2 trials

  11. Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution

    AXIM BIOTECHNOLOGIES, INC.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  12. Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  13. Tasimelteon Oral Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  14. Taxotere , Epirubicin

    Hospital Authority, Hong Kong

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  15. Tebipenem pivoxil, SODIUM CHLORIDE, IMIPENEM AND CILASTATIN , Placebo to match Tebipenem pivoxil, tablet

    Spero Therapeutics

    complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  16. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  17. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    phase 3 small molecule active

    1 trial

  18. Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE

    BioNTech SE

    English First-line extensive-stage small-cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  19. Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  20. Tegafur-Gimeracil-Oteracil Potassium

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasm

    phase 3 small molecule completed

    1 trial

  21. Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)

    Eastern Hepatobiliary Surgery Hospital

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  22. Tenecteplase

    Hospital Authority, Hong Kong

    Ischemic Stroke

    phase 3 small molecule active

    1 trial

  23. Tenecteplase (0.0938mg/kg)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 3 small molecule active

    1 trial

  24. Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources